Department of Pediatric Cardiology, Ümraniye Education and Research Hospital, İstanbul, Turkey
Department of Pediatric Cardiology, Faculty of Medicine, Kırıkkale University, Kırıkkale, Turkey
Turk J Med Sci. 2021 Aug 30;51(4):1833-1840. doi: 10.3906/sag-2004-220.
BACKGROUND/AIM: To evaluate the pre and post-treatment heart rate and oxygen (O2) saturation values measured before, during and after 6MWT in children who received PAH-specific treatment and to determine the effect of these variables on prognosis.
This retrospective study included 29 patients who were diagnosed as PAH and treated. The transcutaneous O2 saturation and heart rate levels were recorded before the test: baseline (Sat0, HR0), at the end of the test: exercise (Sat1, HR1) and 5 min after the test: recovery (Sat2, HR2). The increase in heart rate was defined as HR1-HR0 and the decrease in saturation as Sat0-Sat1. The results obtained before and after the PAH-specific treatment were analyzed and their effect on survival was assessed.
Fifteen of 29 patients were female (51.7%). The mean age was 127.2 ± 44.8 months and the median follow-up time was 60 (12–156) months. Only pre-treatment HR1 was found associated with survival. The mean HR1 value of survivors was 122.8 ± 18.4 and that of deceased 94.3 ± 19.1 (p = 0.03). Post-treatment 6MWT was associated with survival. It was 453.3 ± 96.5 m for survivors and 250 ± 135.2 m for deceased (p = 0.02).
Post-treatment 6MWT, FC and proBNP had prognostic value in pediatric patients with PAH. The decrease in saturation and increase in heart rate were not found to have a prognostic value. Pre-treatment HR1 was associated with survival. Identification of these prognostic factors at the beginning and throughout the treatment may be a guide for detecting the severity of the disease and follow-up.
背景/目的:评估接受肺动脉高压(PAH)特异性治疗的儿童在 6MWT 前后测量的心率和氧(O2)饱和度值,并确定这些变量对预后的影响。
这项回顾性研究纳入了 29 名被诊断为 PAH 并接受治疗的患者。在测试前记录经皮氧饱和度和心率水平:基础值(Sat0,HR0)、测试结束时:运动(Sat1,HR1)和测试后 5 分钟:恢复(Sat2,HR2)。心率的增加定义为 HR1-HR0,饱和度的降低定义为 Sat0-Sat1。分析 PAH 特异性治疗前后的结果,并评估其对生存率的影响。
29 名患者中 15 名(51.7%)为女性。平均年龄为 127.2±44.8 个月,中位随访时间为 60(12-156)个月。仅治疗前的 HR1 与生存率相关。幸存者的平均 HR1 值为 122.8±18.4,死亡者为 94.3±19.1(p=0.03)。治疗后的 6MWT 与生存率相关。幸存者为 453.3±96.5m,死亡者为 250±135.2m(p=0.02)。
治疗后 6MWT、FC 和 proBNP 对儿科 PAH 患者具有预后价值。饱和度降低和心率增加与预后无关。治疗前的 HR1 与生存率相关。在开始治疗和整个治疗过程中识别这些预后因素可能有助于发现疾病的严重程度和进行随访。